よむ、つかう、まなぶ。
05資料2-1森野委員提出資料（RSウイルス母子免疫ワクチンと抗体製剤ファクトシート） (48 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64997.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第32回 10／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
78.
Jasset OJ, Lopez Zapana PA, Bahadir Z, et al. Enhanced placental antibody transfer efficiency
with longer interval between maternal respiratory syncytial virus vaccination and birth. Am J Obstet
Gynecol 2025; 232(6): 554.e1-.e15.
79.
Otsuki T, Akada S, Anami A, et al. Efficacy and safety of bivalent RSVpreF maternal
vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized
phase 3 MATISSE trial. Vaccine 2024; 42(22): 126041.
80.
Fleming-Dutra KE. Evidence to Recommendations Framework Updates Pfizer Maternal
RSVpreF Vaccine (ACIP General Meeting slide September 22, 2023). 2023.
https://www.cdc.gov/acip/downloads/slides-2023-09-22/06-Mat-Peds-Fleming-Dutra-508.pdf (accessed
2025/03/08).
81.
Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer Respiratory Syncytial Virus
Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower
Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization
Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72(41): 1115-22.
82.
Pérez Marc G, Vizzotti C, Fell DB, et al. Real-world effectiveness of RSVpreF vaccination during
pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants
during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative,
case-control study. Lancet Infect Dis 2025.
83.
Williams TC, Marlow R, Cunningham S, et al. Bivalent prefusion F vaccination in pregnancy
and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, testnegative, case-control study. Lancet Child Adolesc Health 2025; 9(9): 655-62.
84.
Jones CJ. Maternal/Pediatric RSV Work Group Considerations. 2024.
https://www.cdc.gov/acip/downloads/slides-2024-06-26-28/05-RSV-Mat-Peds-Jones-508.pdf (accessed
2025/03/08).
85.
Walsh EE, Falsey AR, Zareba AM, et al. Respiratory Syncytial Virus Prefusion F Vaccination:
Antibody Persistence and Revaccination. J Infect Dis 2024; 230(4): e905-e16.
86.
Peterson JT, Zareba AM, Fitz-Patrick D, et al. Safety and Immunogenicity of a Respiratory
Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular
Pertussis Vaccine. J Infect Dis 2022; 225(12): 2077-86.
87.
Griffin MP, Yuan Y, Takas T, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm
Infants. N Engl J Med 2020; 383(5): 415-25.
88.
Wilkins D, Wählby Hamrén U, Chang Y, et al. RSV Neutralizing Antibodies Following
Nirsevimab and Palivizumab Dosing. Pediatrics 2024; 154(5).
89.
Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for Prevention of Hospitalizations Due to
RSV in Infants. N Engl J Med 2023; 389(26): 2425-35.
90.
Munro APS, Drysdale SB, Cathie K, et al. 180-day efficacy of nirsevimab against hospitalisation
for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised,
controlled, phase 3b trial. Lancet Child Adolesc Health 2025; 9(6): 404-12.
48
Jasset OJ, Lopez Zapana PA, Bahadir Z, et al. Enhanced placental antibody transfer efficiency
with longer interval between maternal respiratory syncytial virus vaccination and birth. Am J Obstet
Gynecol 2025; 232(6): 554.e1-.e15.
79.
Otsuki T, Akada S, Anami A, et al. Efficacy and safety of bivalent RSVpreF maternal
vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized
phase 3 MATISSE trial. Vaccine 2024; 42(22): 126041.
80.
Fleming-Dutra KE. Evidence to Recommendations Framework Updates Pfizer Maternal
RSVpreF Vaccine (ACIP General Meeting slide September 22, 2023). 2023.
https://www.cdc.gov/acip/downloads/slides-2023-09-22/06-Mat-Peds-Fleming-Dutra-508.pdf (accessed
2025/03/08).
81.
Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer Respiratory Syncytial Virus
Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower
Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization
Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72(41): 1115-22.
82.
Pérez Marc G, Vizzotti C, Fell DB, et al. Real-world effectiveness of RSVpreF vaccination during
pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants
during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative,
case-control study. Lancet Infect Dis 2025.
83.
Williams TC, Marlow R, Cunningham S, et al. Bivalent prefusion F vaccination in pregnancy
and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, testnegative, case-control study. Lancet Child Adolesc Health 2025; 9(9): 655-62.
84.
Jones CJ. Maternal/Pediatric RSV Work Group Considerations. 2024.
https://www.cdc.gov/acip/downloads/slides-2024-06-26-28/05-RSV-Mat-Peds-Jones-508.pdf (accessed
2025/03/08).
85.
Walsh EE, Falsey AR, Zareba AM, et al. Respiratory Syncytial Virus Prefusion F Vaccination:
Antibody Persistence and Revaccination. J Infect Dis 2024; 230(4): e905-e16.
86.
Peterson JT, Zareba AM, Fitz-Patrick D, et al. Safety and Immunogenicity of a Respiratory
Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular
Pertussis Vaccine. J Infect Dis 2022; 225(12): 2077-86.
87.
Griffin MP, Yuan Y, Takas T, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm
Infants. N Engl J Med 2020; 383(5): 415-25.
88.
Wilkins D, Wählby Hamrén U, Chang Y, et al. RSV Neutralizing Antibodies Following
Nirsevimab and Palivizumab Dosing. Pediatrics 2024; 154(5).
89.
Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for Prevention of Hospitalizations Due to
RSV in Infants. N Engl J Med 2023; 389(26): 2425-35.
90.
Munro APS, Drysdale SB, Cathie K, et al. 180-day efficacy of nirsevimab against hospitalisation
for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised,
controlled, phase 3b trial. Lancet Child Adolesc Health 2025; 9(6): 404-12.
48